Genmab (GMAB) delivered a clean bottom-line beat for the third quarter. It earned $0.56 per share against a $0.36 consensus, a 55.6% surprise. Revenue of $1.187 billion rose 16.1% from a year ago but came in 1.1% below the $1.20 billion consensus, and earnings fell 13.8% year over year. That mix captures the quarter's central tension. The financial engine is still growing but visibly decelerating. Meanwhile, the pipeline story has been transformed by three positive Phase 3 readouts in October, and the market spent the weeks before the report pricing in that transformation.

The quality of the beat deserves scrutiny. Nine-month revenue grew 22% to $3,238 million, driven by DARZALEX and Kesimpta royalties and a 47% jump in EPKINLY/TEPKINLY sales to $491 million. The 16.1% third-quarter growth rate, however, sits well below that year-to-date pace, which had been 25% through the first half. Costs are rising faster than revenue:

• **Adjusted operating expenses** rose 27% to $1,896 million as Genmab builds commercial infrastructure for Rina-S and petosemtamab.
• **Cost of product sales** jumped 49% on AbbVie profit-sharing.
• **Merus-related charges** added $87 million of integration costs and lifted amortization to $35 million.

As a result, IFRS operating profit for nine months slipped to $986 million from $1,007 million. Even adjusted operating profit grew just 9% year to date, down from 18% at the half and 23% in the first quarter. The call also flagged a 3.4% effective tax rate expected to normalize over 12 to 18 months. The EPS beat is therefore real, but it arrives alongside an unusually favorable tax line and does not reflect accelerating profitability.

Beneath the headline, the commercial trends are mixed. Darzalex net sales at J&J grew 19% through nine months, easing from 21% at the half. The more pointed concern is Epkinly, Genmab's own lead product. Implied third-quarter sales of roughly $179 million were essentially flat with about $175 million in the second quarter, after 28% sequential growth the prior quarter. Management pointed to broader adoption, with customers ordering from two or more sites rising above 97% from above 90%, and to the Japan launch in second-line follicular lymphoma. It offered no clear path to reacceleration before a potential frontline approval, however, so bears have legitimate ammunition on near-term product momentum.

Guidance points the other way. The press release says Genmab is maintaining its August 2026 guidance. On the call, management indicated a revenue range of roughly $4.325 billion to $4.525 billion, said it now expects to land in the upper part, and said operating profit should come in above the midpoint of its roughly $1.065 billion to $1.35 billion range. Management also said it expects operating profit to grow in 2027 and gross leverage to stay under 3x, while flagging a substantial fourth-quarter step-up in spending.

The pipeline is what genuinely changed the investment setup:

• **EPCORE DLBCL-2:** epcoritamab plus R-CHOP posted a PFS hazard ratio of 0.49 in frontline diffuse large B-cell lymphoma.
• **RAINFOL-02:** Rina-S hit on PFS (HR 0.29) and OS in platinum-resistant ovarian cancer, regardless of FRα expression.
• **LiGeR-HN1:** petosemtamab met both primary endpoints, OS (HR 0.5) and response rate, in first-line head and neck cancer.

In the second quarter these were pending catalysts that drew skepticism. They now underpin multiple regulatory submissions and potential 2027 launches. Management reaffirmed peak-sales ambitions of more than $3 billion for Epkinly, more than $2 billion for Rina-S, and multi-billion for petosemtamab, including $1 billion by 2029. Notably, it declined to raise those targets or provide medium-term guidance. Upcoming catalysts include a December 16 R&D/ASH event and the LiGeR-HN2 survival readout in early 2027. Remaining risks include immature DLBCL-4 overall survival data with a slight imbalance in grade 5 events, and intense competition from Polivy-based regimens, amivantamab and rival ADCs.

Investor sentiment shifted dramatically, moving from essentially neutral (0.0065) after the August report to strongly positive (0.7186). The stock has moved even more sharply. Shares closed at $55.12 on the eve of the report, up 86.8% from the $29.50 post-August open and nearly 79% above the $30.85 200-day moving average. They set a 52-week high of $59.97 on October 28 and sit about 8% below that peak. The Earnings Whispers trend signals are uniformly positive. The market setup is more complicated than the surprise implies: much of the Phase 3 upside was priced before the report, while the quarter itself showed decelerating revenue and profit growth and stalled Epkinly sales.

The bottom line is that Genmab used this report to convert a speculative pipeline into a de-risked late-stage portfolio, and to signal guidance at the upper end. The near-term financials are weakening, with slowing revenue growth, compressing profit growth, flat Epkinly and a rising cost base. With shares near their highs and sentiment sharply more optimistic, investors are now paying for 2027 launches. The next leg likely depends less on quarterly beats than on regulatory execution and evidence that Epkinly can resume growth.